Tumor Microenvironment

肿瘤微环境

• 批准号: 10626504
• 负责人: Pamela K Kreeger
• 金额: $ 11.51万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-25 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10626504
• 关键词: Affect; Biological; Biological Markers; Biomedical Engineering; Biomimetics; Breast; Budgets; Cancer Model; Catchment Area; Cells; Clinical; Clinical Trials; Collaborations; Complex; Comprehensive Cancer Center; Development; Direct Costs; Extracellular Matrix; Faculty; Fibroblasts; Fostering; Foundations; Funding; Genetic; Goals; Grant; Growth; Heterogeneity; High Prevalence; Image; Immune; Immunology; Innovative Therapy; Institution; Instruction; Intervention; Invaded; Investigation; Investments; Leadership; Legal patent; Licensing; Macrophage; Malignant Neoplasms; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Mediating; Mentors; Metabolism; Microfluidics; Mission; Modality; Modeling; Natural Killer Cells; Nature; Neoplasm Circulating Cells; Neoplasm Metastasis; Paracrine Communication; Patients; Peer Review; Physicians; Pilot Projects; Population; Productivity; Prostate; Publications; Reproduction spores; Research; Research Priority; Research Support; Role; Science; Scientist; Strategic Planning; Stromal Cells; System; T-Lymphocyte; Technology; Therapeutic; Tumor Angiogenesis; Tumor Cell Migration; Work; biomarker driven; biomarker identification; cancer biomarkers; cancer imaging; cell type; clinical development; imaging modality; in vitro Model; malignant breast neoplasm; member; multidisciplinary; neoplastic cell; neutrophil; new technology; optical imaging; patient response; precision medicine; programs; recruit; resistance mechanism; response; response biomarker; success; therapy resistant; trafficking; treatment response; tumor; tumor growth; tumor immunology; tumor initiation; tumor microenvironment; tumor progression; tumorigenesis

UWCCC Tumor Microenvironment Program Summary Co-Leaders: Pamela Kreeger and Josh Lang PROJECT SUMMARY/ABSTRACT Cancer does not develop in isolation, evolving instead in a complex milieu of reactive stroma and immune cells that constitute the tumor microenvironment. Dynamic interactions between cancer-associated fibroblasts (CAFs), immune cells, and the extracellular matrix (ECM) have been shown to enhance tumor growth, initiate the metastatic cascade, and promote treatment resistance in a variety of cancers. Therapeutic advances have confirmed the incredible potential of targeting the tumor microenvironment but also identified unexpected heterogeneity in response and diverse mechanisms of resistance. Therefore, it is the mission of the Tumor Microenvironment (TM) Program to identify microenvironmental changes that occur during tumorigenesis and analyze how the interactions between the tumor cell and microenvironmental components affect tumor formation, growth, metastasis, and response to therapies. Through these research efforts, members of the TM program are identifying new biomarkers and therapeutic approaches. To accomplish these goals, the TM program fosters collaborations between its 33 members from 14 departments across campus, which include biologists, bioengineers, and clinicians. The TM program is pursuing three Specific Aims, with an emphasis on UWCCC priority targets breast and prostate cancer due to their high prevalence in our catchment: Aim 1: Dissect the role of the extracellular matrix in tumor initiation and metastasis. Aim 2: Analyze multi-cellular interactions within the tumor microenvironment during tumor initiation and metastasis. Aim 3: Interrogate the biological interactions in the tumor microenvironment that mediate treatment response and resistance. TM members were supported by $3.5 million direct costs in NCI funding and $5.1 million direct costs in additional peer-reviewed cancer-related support in the last budget year, and were highly productive with 696 cancer- relevant publications during the course of the last grant cycle. Of these publications, 17% were intra- programmatic collaborations and 32% were inter-programmatic collaborations, increases from the previous cycle. In the year 2021 alone, nearly half of publications were collaborative with other institutions.

UWCCC肿瘤微环境项目总结 联合领导人：Pamela Kreeger和Josh Lang 项目总结/摘要 癌症不会孤立地发展，而是在反应性基质和免疫细胞的复杂环境中进化 构成了肿瘤微环境。癌相关成纤维细胞之间的动态相互作用 细胞因子（CAF）、免疫细胞和细胞外基质（ECM）已经显示出增强肿瘤生长、启动肿瘤细胞增殖、诱导肿瘤细胞凋亡和诱导肿瘤细胞凋亡。 转移级联，并促进各种癌症的治疗抗性。治疗进展 证实了靶向肿瘤微环境的难以置信的潜力，但也发现了意想不到的 反应的异质性和抗性机制的多样性。因此，肿瘤的使命 微环境（TM）计划，以确定肿瘤发生期间发生的微环境变化， 分析肿瘤细胞和微环境成分之间的相互作用如何影响肿瘤形成， 生长、转移和对治疗的反应。通过这些研究工作，TM计划的成员 确定新的生物标志物和治疗方法。为了实现这些目标，TM计划促进 来自校园14个部门的33名成员之间的合作，其中包括生物学家， 生物工程师和临床医生。TM计划追求三个具体目标，重点是UWCCC 由于乳腺癌和前列腺癌在我们流域的发病率很高，因此优先目标是乳腺癌和前列腺癌： 目的1：探讨细胞外基质在肿瘤发生和转移中的作用。 目的2：分析肿瘤发生过程中肿瘤微环境中的多细胞相互作用， 转移 目的3：探讨肿瘤微环境中介导治疗反应的生物学相互作用 和抵抗 TM成员得到了NCI资金中350万美元的直接费用和额外510万美元的直接费用的支持。 在上一个预算年度，同行评审的癌症相关支持，并与696癌症， 在最后一个赠款周期期间，出版了相关出版物。在这些出版物中，17%是内部出版物， 方案合作和32%是跨方案合作，比以前增加 周期仅在2021年，近一半的出版物是与其他机构合作的。